OSTX · OS Therapies Inc
$1.30
+0.03 (+2.36%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the unaudited consolidated financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$58.58M
Shares
46.13M
Volume · Oct 20
109.51K
Avg daily vol (3M)
581.18K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.27
Open$1.33
Day$1.23–1.34
52W close$1.16–2.24
Avg vol 30d826K
Short int2.6M · 5.6% float · 3.9d
Short vol35%
DataAug 2024–Oct 2026
Filing10-Q · Aug 14
Up next
filed Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$39.37M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+74.8%
Year over year · more shares
Price change (1Y)
-31.4%
Trailing year
Short interest
5.6%
Latest settlement · 3.9 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−19%
below
Price vs 50-day avg
−22%
below
RSI (14)
28
oversold
MACD trend
Negative
52-week position
10%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−27%
trailing
6-month return
−22%
trailing
YTD return
−9%
this year
Relative strength
−30%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
3 of 29 funds reported for Sep 30 · net +20.0K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.63% of float · ▲ +22.7% MoM · 3.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
29 holders — near 2-yr high, broad support
Squeeze score
60
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
74%
annualized · 1-yr
Max drawdown
−43%
past year
ATR
8.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−19%
Bearish
Price vs 50-day avg
−22%
Bearish
RSI (14)
28
Neutral
MACD trend
Negative
Bearish
52-week position
10%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
3 of 29 funds reported for Sep 30 · net +20.0K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.63% of float · ▲ +22.7% MoM · 3.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
29 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $1 · 10%
Range high $2
vs 200-day avg -19%
vs 50-day avg -22%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OSTX
this stock
OS Therapies Inc
|
$58.58M | -9.3% | — | — | 5.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.07B | +10.7% | +46.2% | 29.9 | 1.8% |
|
MRNA
Moderna, Inc.
|
$90.58B | +669.4% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.51B | +1.3% | +20.8% | 19.4 | 2.1% |
|
CSLLY
Csl Ltd
|
$64.50B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
SEC Filings
Latest
8-K
- Filed
- Oct 19, 2026
- This year
- 23
OS Therapies completed an initial closing on October 15, 2026 of a warrant inducement to exercise at $1.30 per share, with seven participants exercising warrants for 5,517,253 shares and yielding approximately $7.2 million in gross proceeds.
ViewEarnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OSTX | -18.6% | -27.0% | -22.1% | -20.6% | -9.3% |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | -17.1% | -26.1% | -29.8% | -21.1% | -21.7% |